Pembrolizumab for BCG-unresponsive high-risk NMIBC: Considerations for use

December 3, 2020
Urology Times staff

Arjun V. Balar, MD, walks through the patient discussion when weighing the use of pembrolizumab (Keytruda).

In this video, Arjun V. Balar, MD, explains what a urologist should look for or consider regarding tumor and patient characteristics when deciding on use of pembrolizumab in patients with BCG-unresponsive, high-risk non–muscle invasive bladder cancer. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.